These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 18345957)

  • 1. Tamsulosin MR and OCAS (modified release and oral controlled absorption system): current therapeutic uses.
    Nargund VH; Grey AD
    Expert Opin Pharmacother; 2008 Apr; 9(5):813-24. PubMed ID: 18345957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
    Lowe FC
    Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamsulosin modified release and oral controlled absorption system in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Schulman CC
    Expert Opin Drug Metab Toxicol; 2008 Jun; 4(6):771-82. PubMed ID: 18611117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamsulosin: the United States trials.
    Narayan P
    Geriatrics; 1998 Oct; 53 Suppl 2():S29-32. PubMed ID: 9789483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia.
    Fitzpatrick JM; Desgrandchamps F
    BJU Int; 2005 Mar; 95(4):575-9. PubMed ID: 15705083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms.
    Barqawi AB; Myers JB; O'Donnell C; Crawford ED
    BJU Int; 2007 Oct; 100(4):853-7. PubMed ID: 17662074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
    Masumori N; Tsukamoto T; Iwasawa A; Furuya R; Sonoda T; Mori M;
    Urol Int; 2009; 83(1):49-54. PubMed ID: 19641359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL).
    Michel MC; Chapple CR
    Eur Urol; 2006 Mar; 49(3):501-8; discussion 508-9. PubMed ID: 16442211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia.
    Lucas MG; Stephenson TP; Nargund V
    BJU Int; 2005 Feb; 95(3):354-7. PubMed ID: 15679793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients.
    Xue Z; Zhang Y; Ding Q; He Z; Wang J; Xu K
    Int J Urol; 2007 Feb; 14(2):118-22. PubMed ID: 17302567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
    Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch from phytotherapy to tamsulosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH).
    Gross AJ; Busse M; Leonard J; Schumacher H
    Prostate Cancer Prostatic Dis; 2005; 8(3):210-4. PubMed ID: 15883586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tamsulosin in the sustained-release capsule -- continuously effective and economical].
    MMW Fortschr Med; 2006 Apr; 148(17):56-7. PubMed ID: 16711490
    [No Abstract]   [Full Text] [Related]  

  • 18. Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia.
    Kojima Y; Sasaki S; Kubota Y; Hayase M; Hayashi Y; Shinoura H; Tsujimoto G; Kohri K
    J Urol; 2008 Mar; 179(3):1040-6. PubMed ID: 18206918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience.
    Chapple CR
    Eur Urol; 1996; 29(2):129-44. PubMed ID: 8647139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting.
    Flannery MT; Ramsdell J; Ranhosky A; Davidai G; Ruoff G
    Curr Med Res Opin; 2006 Apr; 22(4):721-30. PubMed ID: 16684433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.